Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To demonstrate that the efficacy of at least one dose of secukinumab at Week 16 is superior to placebo based on the proportion of subjects achieving an ASAS 20 (Assessment of SpondyloArthritis International Society criteria) response in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF alpha therapy.
Inclusion criteria
- Ankylosing spondylitis